Join today and pick your exclusive member gift

Exploring the Cost-Effectiveness of RSV Vaccines in Older Adults

July 18, 2023

 • 

Read time:

5-15 mins
Vaccines Web 670x350px

Each year, respiratory syncytial virus (RSV) hospitalizes an estimated 60,000-160,000 older US adults. After decades of development, the FDA approved two vaccines for older adults. In this faculty Q&A, Dave Hutton, a U-M professor of Health Management and Policy and Global Public Health, explores the potential cost-effectiveness of these vaccines.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.